Role of Heparan Sulfates and Glycosphingolipids in the Pore Formation of Basic Polypeptides of Cobra Cardiotoxin

  • Wen-guey Wu
  • Siu-Cin Tjong
  • Po-long Wu
  • Je-hung Kuo
  • Karen Wu
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 677)

Abstract

Cobra venom contains cardiotoxins (CTXs) that induce tissue necrosis and systolic heart arrest in bitten victims. CTX-induced membrane pore formation is one of the major mechanisms responsible for the venom’s designated cytotoxicity. This chapter examines how glycoconjugates such as heparan sulfates (HS) and glycosphingolipids, located respectively in the extracellular matrix and lipid bilayers of the cell membranes, facilitate CTX pore formation. Evidences for HS-facilitated cell surface retention and glycosphingolipid-facilitated membrane bilayer insertion of CTX are reviewed. We suggest that similar physical steps could play a role in the mediation of other pore forming toxins (PFT). The membrane pores formed by PFT are expected to have limited lifetime on biological cell surface as a result of membrane dynamics during endocytosis and/or rearrangement of lipid rafts.

Keywords

Carbohydrate Citrate Pneumonia Heparin Oligomerization 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lindahl U. Heparan sulfate-protein interactions—a concept for drug design? Thromb Haemost 2007; 98:109–115.PubMedGoogle Scholar
  2. 2.
    Murphy JW, Cho Y, Sachpatzidis A et al. Structural and functional basis of CXCL12 (stromal cell-derived factor-1 alpha) binding to heparin. J Biol Chem 2007; 282:10018–10027.CrossRefPubMedGoogle Scholar
  3. 3.
    Schenauer MR, Yu Y, Sweeney MD et al. CCR2 chemokines bind selectively to acetylated heparan sulfate octasaccharides. J Biol Chem 2007; 282:25182–25188.CrossRefPubMedGoogle Scholar
  4. 4.
    Laguri C, Arenzana-Seisdedos F, Lortat-Jacob H. Relationships between glycosaminoglycan and receptor binding sites in chemokines-the CXCL12 example. Carbohydr Res 2008; 343:2018–2023.CrossRefPubMedGoogle Scholar
  5. 5.
    Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 2006; 20:9–22.CrossRefPubMedGoogle Scholar
  6. 6.
    Lajoie P, Goetz JG, Dennis JW et al. Lattices, rafts and scaffolds: domain regulation of receptor signaling at the plasma membrane. J Cell Biochem 2009; 185:381–385.Google Scholar
  7. 7.
    Holthuis JC, Levine TP. Lipid traffic: floppy drives and a superhighway. Nat Rev Mol Cell Biol 2005; 6:209–220.CrossRefPubMedGoogle Scholar
  8. 8.
    Sillence DJ. New insights into glycosphingolipid functions—storage, lipid rafts and translocators. Int Rev Cytol 2007; 262:151–189.CrossRefPubMedGoogle Scholar
  9. 9.
    Eggeling C, Ringemann C, Medda R et al. Direct observation of the nanoscale dynamics of membrane lipids in a living cell. Nature 2009; 457:1159–1163.CrossRefPubMedGoogle Scholar
  10. 10.
    Gilbert RJC, Jimenez JL, Chen S et al. Two structural transitions in membrane pore formation by pneumolysin, the pore-forming toxin of Streptococcus pneumonia. Cell 1999; 97:647–655.CrossRefPubMedGoogle Scholar
  11. 11.
    Walz T. How cholesterol-dependent cytolysins bite holes into membranes. Mol Cell 2005; 18:393–394.CrossRefPubMedGoogle Scholar
  12. 12.
    Tilley SJ, Orlova EV, Gilbert RJC et al. Structural basis of pore formation by the bacterial toxin pneumolysin. Cell 2005; 121:247–256.CrossRefPubMedGoogle Scholar
  13. 13.
    Taylor K, Barran PE, Dorin JR. Structure-activity relationships in beta-defensin peptides. Biopolymers 2008; 90:1–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Aerts AM, François IE, Cammue BP et al. The mode of antifungal action of plant, insect and human defensins. Cell Mol Life Sci 2008; 65:2069–2079.CrossRefPubMedGoogle Scholar
  15. 15.
    Chien KY, Chiang CM, Hseu YC et al. Two distinct types of cardiotoxin as revealed by the structure and activity relationship of their interaction with zwitterionic phospholipid dispersions. J Biol Chem 1994; 269:14473–14483.PubMedGoogle Scholar
  16. 16.
    Efremov RG, Volynsky PE, Nolde DE et al. Interaction of cardiotoxins with membranes: a molecular modeling study. Biophys J 2002; 83:144–53.CrossRefPubMedGoogle Scholar
  17. 17.
    Lai MK, Wen CY, Lee CY. Local lesions1 caused by cardiotoxin isolated from Formosan cobra venom. J Formosan Med Assoc 1972; 71:328–332.Google Scholar
  18. 18.
    Hider RC, Khader F. Biochemical and pharmacological properties of cardiotoxins isolated from cobra venom. Toxicon 1982; 20:175–179.CrossRefPubMedGoogle Scholar
  19. 19.
    Sun JJ, Walker MJ. Actions of cardiotoxins from the southern Chinese cobra (Naja naja atra) on rat cardiac tissue. Toxicon 1986; 24:233–245.CrossRefPubMedGoogle Scholar
  20. 20.
    Dufton MJ, Hider RC. Structure and pharmacology of elapid cytotoxins. Pharmacol Ther. 1988; 36:1–40.CrossRefPubMedGoogle Scholar
  21. 21.
    Fletcher JE, Jiang MH. Possible mechanisms of action of cobra snake venom cardiotoxins and bee venom melittin. Toxicon 1993; 31:669–695.CrossRefPubMedGoogle Scholar
  22. 22.
    Lee SC, Guan HH, Wang CH. Structural basis of citrate-dependent and heparin sulfate-mediated cell surface retention of cobra cardiotoxin A3. J Biol Chem 2005; 280:9567–9577.CrossRefPubMedGoogle Scholar
  23. 23.
    Wu PL, Lee SC, Chuang CC et al. Non-cytotoxic cobra cardiotoxin A5 binds to avß3 integrin and inhibit bone resorption. Identification of cardiotoxins as nonRGD integrin-binding proteins of the Ly-6 family. J Biol Chem 2006; 281:7937–7945.CrossRefPubMedGoogle Scholar
  24. 24.
    Wang CH, Liu JH, Lee SC et al. Glycosphingolipid-facilitated membrane insertion and internalization of cobra cardiotoxin. J Biol Chem 2006; 281:656–667.CrossRefPubMedGoogle Scholar
  25. 25.
    Tjong SC, Chen TS, Huang WN et al. Structures of heparin-derived tetrasaccharide bound to cobra cardiotoxins: Heparin binding at a single protein site with diverse side chain interactions. Biochemistry 2007; 46:9941–9952.CrossRefPubMedGoogle Scholar
  26. 26.
    Vyas KA, Patel HM, Vyas AA et al. Glycosaminoglycans bind to homologous cardiotoxins with different specificity. Biochemistry 1998; 37:4527–4534CrossRefPubMedGoogle Scholar
  27. 27.
    Schlessinger J, Plotnikov AN, Ibrahimi OA et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 2000; 6:43–50.CrossRefGoogle Scholar
  28. 28.
    Sue SC, Chien KY, Huang WN et al. Heparin binding stabilizes the membrane-bound form of cobra cardiotoxin. J Biol Chem 2002; 277:2666–2673.CrossRefPubMedGoogle Scholar
  29. 29.
    Tjong SC, Wu PL, Wang CM et al. Role of glycosphingolipid conformational change in membrane pore forming activity of cobra cardiotoxin. Biochemistry 2007; 46:12111–12123.CrossRefPubMedGoogle Scholar
  30. 30.
    Leontiadou H, Mark AE, Marrink SJ. Antimicrobial peptides in action. J Am Chem Soc 2006; 128:12156–12161.CrossRefPubMedGoogle Scholar
  31. 31.
    Melo MN, Ferre R, Castanho MA. Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations. Nat Rev Microbiol 2009; 7:245–250.CrossRefPubMedGoogle Scholar
  32. 32.
    Dowhan W, Bogdanov M. Lipid-dependent membrane protein topogenesis. Annu Rev Biochem 2009; 78:5.1–5.26.CrossRefGoogle Scholar
  33. 33.
    Idone V, Tam C, Goss JW et al. Repair of injured plasma membrane by rapid Ca2±dependent endocytosis. J Cell Biol 2008; 180:905–914.CrossRefPubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2010

Authors and Affiliations

  • Wen-guey Wu
    • 1
  • Siu-Cin Tjong
    • 1
  • Po-long Wu
    • 1
  • Je-hung Kuo
    • 1
  • Karen Wu
    • 1
  1. 1.National Synchrotron Radiation Research Center and Department of Life ScienceNational Tsing Hua UniversityHsinchuTaiwan

Personalised recommendations